Ciyu Yang1, Angela G Arnold2, Magan Trottier2, Yukio Sonoda3, Nadeem R Abu-Rustum3, Oliver Zivanovic3, Mark E Robson2, Zsofia K Stadler2, Michael F Walsh2,4, David M Hyman2, Kenneth Offit2, Liying Zhang5,6. 1. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA. 2. Departments of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA. 3. Departments of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA. 4. Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA. 5. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA. zhangl2@mskcc.org. 6. Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 36, New York, NY, 10065, USA. zhangl2@mskcc.org.
Abstract
PURPOSE: Mutations in PALB2 have been associated with a predisposition to breast and pancreatic cancers. This study aims to characterize a novel PALB2 exon 13 duplication in a hereditary breast and ovarian cancer family. METHODS: The PALB2 exon 13 duplication in this family was evaluated using Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT™) and confirmed by multiplex ligation-dependent probe amplification (MLPA). The duplication breakpoints were determined by long-range PCR and DNA sequencing. The effects of this mutation on mRNA splicing were characterized using RT-PCR, cloning, and DNA sequencing. RESULTS: The 5' and 3' breakpoints were mapped to intron 12 and downstream of 3'UTR. The tandem duplication is mediated by Alu elements in these regions. This duplication disrupts normal mRNA splicing and presumably leads to a frameshift and premature protein truncation. This duplication segregates with ovarian and breast cancer in multiple members in this family. CONCLUSIONS: Our results indicate that the PALB2 exon 13 duplication is a pathogenic variant. The presence of the PALB2 duplication in the proband affected with high-grade serous ovarian cancer suggests that PALB2 might be associated with a predisposition to ovarian cancer.
PURPOSE: Mutations in PALB2 have been associated with a predisposition to breast and pancreatic cancers. This study aims to characterize a novel PALB2 exon 13 duplication in a hereditary breast and ovarian cancer family. METHODS: The PALB2 exon 13 duplication in this family was evaluated using Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT™) and confirmed by multiplex ligation-dependent probe amplification (MLPA). The duplication breakpoints were determined by long-range PCR and DNA sequencing. The effects of this mutation on mRNA splicing were characterized using RT-PCR, cloning, and DNA sequencing. RESULTS: The 5' and 3' breakpoints were mapped to intron 12 and downstream of 3'UTR. The tandem duplication is mediated by Alu elements in these regions. This duplication disrupts normal mRNA splicing and presumably leads to a frameshift and premature protein truncation. This duplication segregates with ovarian and breast cancer in multiple members in this family. CONCLUSIONS: Our results indicate that the PALB2 exon 13 duplication is a pathogenic variant. The presence of the PALB2 duplication in the proband affected with high-grade serous ovarian cancer suggests that PALB2 might be associated with a predisposition to ovarian cancer.
Entities:
Keywords:
Breast cancer; Duplication; Ovarian cancer; PALB2; Pathogenic
Authors: Bing Xia; Josephine C Dorsman; Najim Ameziane; Yne de Vries; Martin A Rooimans; Qing Sheng; Gerard Pals; Abdellatif Errami; Eliane Gluckman; Julian Llera; Weidong Wang; David M Livingston; Hans Joenje; Johan P de Winter Journal: Nat Genet Date: 2006-12-31 Impact factor: 38.330
Authors: Barbara M Norquist; Maria I Harrell; Mark F Brady; Tom Walsh; Ming K Lee; Suleyman Gulsuner; Sarah S Bernards; Silvia Casadei; Qian Yi; Robert A Burger; John K Chan; Susan A Davidson; Robert S Mannel; Paul A DiSilvestro; Heather A Lankes; Nilsa C Ramirez; Mary Claire King; Elizabeth M Swisher; Michael J Birrer Journal: JAMA Oncol Date: 2016-04 Impact factor: 31.777
Authors: E P Slater; P Langer; E Niemczyk; K Strauch; J Butler; N Habbe; J P Neoptolemos; W Greenhalf; D K Bartsch Journal: Clin Genet Date: 2010-11 Impact factor: 4.438
Authors: Marketa Janatova; Zdenek Kleibl; Jana Stribrna; Ales Panczak; Kamila Vesela; Martina Zimovjanova; Petra Kleiblova; Pavel Dundr; Jana Soukupova; Petr Pohlreich Journal: Cancer Epidemiol Biomarkers Prev Date: 2013-10-17 Impact factor: 4.254
Authors: Nazneen Rahman; Sheila Seal; Deborah Thompson; Patrick Kelly; Anthony Renwick; Anna Elliott; Sarah Reid; Katarina Spanova; Rita Barfoot; Tasnim Chagtai; Hiran Jayatilake; Lesley McGuffog; Sandra Hanks; D Gareth Evans; Diana Eccles; Douglas F Easton; Michael R Stratton Journal: Nat Genet Date: 2006-12-31 Impact factor: 38.330
Authors: Marc Tischkowitz; Bing Xia; Nelly Sabbaghian; Jorge S Reis-Filho; Nancy Hamel; Guilan Li; Erik H van Beers; Lili Li; Tayma Khalil; Louise A Quenneville; Atilla Omeroglu; Aletta Poll; Pierre Lepage; Nora Wong; Petra M Nederlof; Alan Ashworth; Patricia N Tonin; Steven A Narod; David M Livingston; William D Foulkes Journal: Proc Natl Acad Sci U S A Date: 2007-04-09 Impact factor: 11.205
Authors: Colin C Pritchard; Joaquin Mateo; Michael F Walsh; Navonil De Sarkar; Wassim Abida; Himisha Beltran; Andrea Garofalo; Roman Gulati; Suzanne Carreira; Rosalind Eeles; Olivier Elemento; Mark A Rubin; Dan Robinson; Robert Lonigro; Maha Hussain; Arul Chinnaiyan; Jake Vinson; Julie Filipenko; Levi Garraway; Mary-Ellen Taplin; Saud AlDubayan; G Celine Han; Mallory Beightol; Colm Morrissey; Belinda Nghiem; Heather H Cheng; Bruce Montgomery; Tom Walsh; Silvia Casadei; Michael Berger; Liying Zhang; Ahmet Zehir; Joseph Vijai; Howard I Scher; Charles Sawyers; Nikolaus Schultz; Philip W Kantoff; David Solit; Mark Robson; Eliezer M Van Allen; Kenneth Offit; Johann de Bono; Peter S Nelson Journal: N Engl J Med Date: 2016-07-06 Impact factor: 91.245
Authors: Antonis C Antoniou; Silvia Casadei; Tuomas Heikkinen; Daniel Barrowdale; Katri Pylkäs; Jonathan Roberts; Andrew Lee; Deepak Subramanian; Kim De Leeneer; Florentia Fostira; Eva Tomiak; Susan L Neuhausen; Zhi L Teo; Sofia Khan; Kristiina Aittomäki; Jukka S Moilanen; Clare Turnbull; Sheila Seal; Arto Mannermaa; Anne Kallioniemi; Geoffrey J Lindeman; Saundra S Buys; Irene L Andrulis; Paolo Radice; Carlo Tondini; Siranoush Manoukian; Amanda E Toland; Penelope Miron; Jeffrey N Weitzel; Susan M Domchek; Bruce Poppe; Kathleen B M Claes; Drakoulis Yannoukakos; Patrick Concannon; Jonine L Bernstein; Paul A James; Douglas F Easton; David E Goldgar; John L Hopper; Nazneen Rahman; Paolo Peterlongo; Heli Nevanlinna; Mary-Claire King; Fergus J Couch; Melissa C Southey; Robert Winqvist; William D Foulkes; Marc Tischkowitz Journal: N Engl J Med Date: 2014-08-07 Impact factor: 91.245
Authors: J-Y Park; T R Singh; N Nassar; F Zhang; M Freund; H Hanenberg; A R Meetei; P R Andreassen Journal: Oncogene Date: 2013-10-21 Impact factor: 9.867
Authors: R Garrett Morgan; Massimo Venturelli; Cole Gross; Cantor Tarperi; Federico Schena; Carlo Reggiani; Fabio Naro; Anna Pedrinolla; Lucia Monaco; Russell S Richardson; Anthony J Donato Journal: PLoS One Date: 2017-01-06 Impact factor: 3.240